Cofrogliptin vs Teneligliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Cofrogliptin
Marketed by Haisco Pharmaceutical Group
NCT04556851 · Phase 3 · completed
This randomized, double-blind, placebo-controlled trial enrolled 476 patients and measured change in HbA1c, a standard efficacy measure in diabetes, at 24 weeks. Both HSK7653 doses lowered HbA1c significantly more than placebo (p<0.0001), meeting the trial's primary goal.
Next expected readout: June 2027 · NCT07122102 (registry estimate)
Reported efficacy
HbA1c Change From Baseline at Week 24 (Baseline and week 24): HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin (met)
Result source: NCT04564872
Teneligliptin · Tenelia
Marketed by Tanabe Pharma Corporation and partners
NCT00974090 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 trial added teneligliptin 20 mg or placebo to glimepiride in 194 Japanese adults with type 2 diabetes. The primary endpoint was the change in HbA1c at week 12. Teneligliptin lowered HbA1c by 1.0 percentage point more than placebo (p<0.001), so the primary endpoint was met. A 40-week open-label teneligliptin period followed. Source: the peer-reviewed trial report (Kadowaki and Kondo 2014) and CT.gov posted results.
Reported efficacy
HbA1c (Change from Visit 1(Baseline Visit) in HbA1c at Visit 5(week 16)): Change in HbA1c from baseline to week 16, teneligliptin (MP-513) vs placebo (both plus metformin): between-group difference -0.78 percentage points; fasting plasma glucose difference -1.24 mmol/L (22.42 mg/dL). (met)
Result source: NCT01805830
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cofrogliptin | Teneligliptin |
|---|---|---|
| HbA1c, change | -1.0% vs -1.1%avs linagliptin 5 mgNCT045648721 other result
| -0.7% vs -0.0%−0.7 vs placeboNCT0292406412 other results
|
| Body weight, change (kg) | —Not posted · NCT04564872 | —Not posted · NCT01798238 |
| HbA1c below 7% | —Not posted · NCT04564872 | —Not posted · NCT01798238 |
| Fasting plasma glucose, change | —Not posted · NCT04564872 | -0.8 vs 0.2−0.9 vs placeboNCT0292406413 other results
|
| 3-point MACE (% with event) | —Not posted · NCT04564872 | —Not posted · NCT01798238 |
HbA1c, change
- Cofrogliptin
- -1.0% vs -1.1%avs linagliptin 5 mgNCT04564872
1 other result
- -1.0% vs -1.1% NCT04564872
- Teneligliptin
- -0.7% vs -0.0%−0.7 vs placeboNCT02924064
12 other results
- -0.9% vs -0.1% NCT02916706
- -0.6% vs 0.2% NCT00998881
- -0.9% vs 0% NCT02354222
- -0.7% vs 0.3% NCT00974090
- -0.8% vs 0.1% NCT00628212
- -0.8% vs 0.1% NCT00628212
- -0.9% vs -0.3% NCT00971243
- -0.9% vs 0.1% NCT00628212
- -0.8% vs -0.3% NCT00971243
- -0.7% vs -0.3% NCT00971243
- -0.6% vs -0.3% NCT00971243
- -0.9% vs -0.1% NCT02081599
Body weight, change (kg)
- Cofrogliptin
- —Not posted · NCT04564872
- Teneligliptin
- —Not posted · NCT01798238
HbA1c below 7%
- Cofrogliptin
- —Not posted · NCT04564872
- Teneligliptin
- —Not posted · NCT01798238
Fasting plasma glucose, change
- Cofrogliptin
- —Not posted · NCT04564872
- Teneligliptin
- -0.8 vs 0.2−0.9 vs placeboNCT02924064
13 other results
- -1.2 vs -0.1 NCT02916706
- -1.1 vs -0.0 NCT00998881
- -1.1 vs -0.4 NCT01072331
- -1.1 vs -0.4 NCT01072331
- -0.3 vs 0.6 NCT02354222
- -0.8 vs 0.2 NCT00628212
- -0.8 vs 0.2 NCT00628212
- -1.2 vs -0.2 NCT00971243
- -0.9 vs 0.2 NCT00628212
- -1.0 vs -0.2 NCT00971243
- -0.8 vs -0.2 NCT00971243
- -0.9 vs -0.2 NCT00971243
- -0.3 vs 0.4 NCT02081599
3-point MACE (% with event)
- Cofrogliptin
- —Not posted · NCT04564872
- Teneligliptin
- —Not posted · NCT01798238
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Cofrogliptin: 1 of 5 rows · Teneligliptin: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cofrogliptin Rows use multiple source trials | Teneligliptin Rows use multiple source trials |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.59% @ 24wk25 mga,b,c NCT04556851 · Phase 3 · sponsor-reported, not registry data show 1 more dose-0.63% @ 24wkcofrogliptin (HSK7653) 10 mg NCT04556851 · Phase 3 · sponsor-reported, not registry data | -0.94% @ 24wkteneligliptin 20mgb,c NCT01798238 · Phase 3 · sponsor-reported, not registry data |
| Dropout rate | — | 1%Teneli / Teneli + SUd NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 28 more results—Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 —Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.6%Teneligliptin NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15.7%Teneligliptin + Sulfonylurea NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin)/Teneli + In NCT02081599 · Phase 4 · registry result, not featured evidence · combination 19.5%20 mg NCT02924064 · Phase 3 · registry result, not featured evidence · combination 11.8%20 mg NCT02916706 · Phase 3 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 5.2% NCT02354222 · Phase 3 · registry result, not featured evidence · combination 7.1%Teneligliptin NCT01301833 · Phase 3 · registry result, not featured evidence 9.3%Teneligliptin and Alpha-glucosidas NCT01301833 · Phase 3 · registry result, not featured evidence · combination 7.4%Teneligliptin and Biguanide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 10%Teneligliptin and Glinide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 0%20 mg NCT01072331 · Phase 3 · registry result, not featured evidence 0%10 mg NCT01072331 · Phase 3 · registry result, not featured evidence 2%20 mg NCT00998881 · Phase 3 · registry result, not featured evidence —40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 15.9%40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 20.9%20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 11.8%10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 21.8%5 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 3.8%20 mg NCT00628212 · Phase 2 · registry result, not featured evidence 1.2%10 mg NCT00628212 · Phase 2 · registry result, not featured evidence 6.2%40 mg NCT00628212 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — | 1%Teneli / Teneli + SUd NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 28 more results—Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 —Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%Teneligliptin NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9%Teneligliptin + Sulfonylurea NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination —Teneli (Teneligliptin)/Teneli + In NCT02081599 · Phase 4 · registry result, not featured evidence · combination 1.6%20 mg NCT02924064 · Phase 3 · registry result, not featured evidence · combination 0%20 mg NCT02916706 · Phase 3 · registry result, not featured evidence 4.6% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 0% NCT02354222 · Phase 3 · registry result, not featured evidence · combination 3.3%Teneligliptin NCT01301833 · Phase 3 · registry result, not featured evidence 6.7%Teneligliptin and Alpha-glucosidas NCT01301833 · Phase 3 · registry result, not featured evidence · combination 5.3%Teneligliptin and Biguanide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 6.3%Teneligliptin and Glinide NCT01301833 · Phase 3 · registry result, not featured evidence · combination —20 mg NCT01072331 · Phase 3 · registry result, not featured evidence —10 mg NCT01072331 · Phase 3 · registry result, not featured evidence 2%20 mg NCT00998881 · Phase 3 · registry result, not featured evidence —40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 2.3%40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 2.2%20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 3.2%10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 2.3%5 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 1.3%20 mg NCT00628212 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00628212 · Phase 2 · registry result, not featured evidence 2.5%40 mg NCT00628212 · Phase 2 · registry result, not featured evidence |
| Serious AEs | — | —Teneli / Teneli + SUd NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 28 more results0%Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.3%Teneli/Teneli + SU (Data Through W NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 4%Teneligliptin NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.9%Teneligliptin + Sulfonylurea NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 —Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination 6.5%Teneli (Teneligliptin) /Teneli + I NCT02081599 · Phase 4 · registry result, not featured evidence · combination 1.3%Teneli (Teneligliptin)/Teneli + In NCT02081599 · Phase 4 · registry result, not featured evidence · combination 3.2%20 mg NCT02924064 · Phase 3 · registry result, not featured evidence · combination 4.7%20 mg NCT02916706 · Phase 3 · registry result, not featured evidence 7.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination 1.3% NCT02354222 · Phase 3 · registry result, not featured evidence · combination 6.6%Teneligliptin NCT01301833 · Phase 3 · registry result, not featured evidence 8%Teneligliptin and Alpha-glucosidas NCT01301833 · Phase 3 · registry result, not featured evidence · combination 6.3%Teneligliptin and Biguanide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 3.8%Teneligliptin and Glinide NCT01301833 · Phase 3 · registry result, not featured evidence · combination 0%20 mg NCT01072331 · Phase 3 · registry result, not featured evidence 0%10 mg NCT01072331 · Phase 3 · registry result, not featured evidence 0%20 mg NCT00998881 · Phase 3 · registry result, not featured evidence 5.7%40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —40 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 3.3%20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —20 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 4.3%10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 4.6%5 mg NCT00971243 · Phase 2 · registry result, not featured evidence · combination 0%20 mg NCT00628212 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00628212 · Phase 2 · registry result, not featured evidence 0%40 mg NCT00628212 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | d nasopharyngitis 19.8% (placebo 27.4%) upper respiratory tract inflammation 5.2% (placebo 7.4%) alanine aminotransferase increased 4.2% (placebo 3.2%) NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 23 more resultsnasopharyngitis 33.3% (placebo 27.4%) protein urine present 16.7% (placebo 13.7%) glucose urine present 11.5% (placebo 17.9%) NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 nasopharyngitis 37.1% blood creatine phosphokinase increased 9.3% protein urine present 9.3% NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 nasopharyngitis 32.6% glucose urine present 18% protein urine present 14.6% NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 nasopharyngitis 28.6% (placebo 18.3%) hypoglycaemia 27.3% (placebo 7%) constipation 10.4% (placebo 2.8%) NCT02081599 · Phase 4 · registry result, not featured evidence · combination hypoglycaemia 11.7% (placebo 7%) nasopharyngitis 7.8% (placebo 18.3%) constipation 3.9% (placebo 2.8%) NCT02081599 · Phase 4 · registry result, not featured evidence · combination 20 mg upper respiratory tract infection 11.3% (placebo 17.9%) hyperuricaemia 8.9% (placebo 10.6%) hyperlipidaemia 6.5% (placebo 5.7%) NCT02924064 · Phase 3 · registry result, not featured evidence · combination 20 mg upper respiratory tract infection 23.6% (placebo 15.7%) hyperuricaemia 8.7% (placebo 4.7%) proteinuria 7.1% (placebo 3.9%) NCT02916706 · Phase 3 · registry result, not featured evidence nasopharyngitis 30.7% pollakiuria 6.5% constipation 5.2% NCT02220907 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 15.6% (placebo 10.4%) upper respiratory tract infection 5.2% (placebo 0%) NCT02354222 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 29.2% upper respiratory tract inflammation 9.4% blood urine present 7.1% NCT01301833 · Phase 3 · registry result, not featured evidence nasopharyngitis 28% upper respiratory tract inflammation 10.7% eczema 9.3% NCT01301833 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 29.5% upper respiratory tract inflammation 10.5% blood urine present 9.5% NCT01301833 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 23.8% upper respiratory tract inflammation 13.8% bronchitis 8.8% NCT01301833 · Phase 3 · registry result, not featured evidence · combination 20 mg nasopharyngitis 6.1% (placebo 0%) blood triglycerides increased 3% (placebo 3.1%) diarrhoea 3% (placebo 0%) NCT01072331 · Phase 3 · registry result, not featured evidence 10 mg upper respiratory tract inflammation 8.8% (placebo 0%) nasopharyngitis 5.9% (placebo 0%) alanine aminotransferase increased 2.9% (placebo 0%) NCT01072331 · Phase 3 · registry result, not featured evidence 20 mg nasopharyngitis 12.1% (placebo 6.7%) glucose urine present 4% (placebo 6.7%) upper respiratory tract inflammation 4% (placebo 3.8%) NCT00998881 · Phase 3 · registry result, not featured evidence 40 mg nasopharyngitis 8% (placebo 6.8%) cystitis 5.7% (placebo 1.1%) gastroenteritis 3.4% (placebo 2.3%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 20 mg diarrhoea 5.5% (placebo 3.4%) headache 5.5% (placebo 1.1%) hypertension 3.3% (placebo 2.3%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 10 mg cystitis 4.3% (placebo 1.1%) nasopharyngitis 4.3% (placebo 6.8%) bronchitis 3.2% (placebo 1.1%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 5 mg nasopharyngitis 6.9% (placebo 6.8%) hypertension 5.7% (placebo 2.3%) bronchitis 3.4% (placebo 1.1%) NCT00971243 · Phase 2 · registry result, not featured evidence · combination 20 mg nasopharyngitis 11.4% (placebo 13.8%) glucose urine present 5.1% (placebo 7.5%) urine ketone body present 5.1% (placebo 1.3%) NCT00628212 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 19% (placebo 13.8%) blood creatine phosphokinase increased 4.8% (placebo 1.3%) blood urine present 4.8% (placebo 1.3%) NCT00628212 · Phase 2 · registry result, not featured evidence 40 mg nasopharyngitis 17.3% (placebo 13.8%) arthropod sting 3.7% (placebo 0%) glucose urine present 3.7% (placebo 7.5%) NCT00628212 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Teneligliptin
show 5 more results
show 7 more results
show 13 more results
show 5 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cofrogliptin's landscape · Teneligliptin's landscape